Fungal Infectious Disease

Categories: Infectious diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Fungal Infectious Disease

MalaCards integrated aliases for Fungal Infectious Disease:

Name: Fungal Infectious Disease 11 14
Mycoses 11 43 14 31 33
Mycosis 11


External Ids:

Disease Ontology 11 DOID:1564
ICD9CM 34 110-118.99
MeSH 43 D009181
NCIt 49 C3245
SNOMED-CT 68 154393000
UMLS 71 C0026946

Summaries for Fungal Infectious Disease

Disease Ontology: 11 A disease by infectious agent that results in infection, has material basis in Fungi, which pass the resistance barriers of the human or animal body.

MalaCards based summary: Fungal Infectious Disease, also known as mycoses, is related to sezary's disease and primary cutaneous t-cell non-hodgkin lymphoma. An important gene associated with Fungal Infectious Disease is CCR6 (C-C Motif Chemokine Receptor 6), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Voriconazole and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include skin, liver and t cells, and related phenotypes are homeostasis/metabolism and immune system

Related Diseases for Fungal Infectious Disease

Diseases related to Fungal Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1482)
# Related Disease Score Top Affiliating Genes
1 sezary's disease 32.5 IL4 IL10 CD8A CD4 CCR6
2 primary cutaneous t-cell non-hodgkin lymphoma 32.5 IL4 H2AC18 CD4 CCR6
3 superficial mycosis 32.3 CLEC7A CLEC6A CD4 CCR6 CARD9
4 subcutaneous mycosis 32.1 TLR2 IL17A IL10 CLEC7A CLEC6A CD4
5 histoplasmosis 32.1 TNF CLEC7A CLEC6A CD4 CCR6
6 primary systemic mycosis 31.9 TNF TLR2 IL6 IL4 IL1B IL17A
7 coccidioidomycosis 31.8 IL17A CYP51A1 CLEC7A CLEC6A CD4 CCR6
8 sporotrichosis 31.8 TNF IL10 CLEC7A CLEC6A CD4 CARD9
9 chromoblastomycosis 31.8 IL4 CLEC7A CLEC6A CCR6 CARD9
10 paracoccidioidomycosis 31.7 TNF TLR2 IL6 IL4 IL10
11 pityriasis versicolor 31.7 CLEC7A CLEC6A CCR6 CARD9
12 cryptococcosis 31.6 TNF IL4 IL17A IL10 CYP51A1 CLEC7A
13 opportunistic mycosis 31.6 TNF TLR2 IL6 IL4 IL1B IL17RA
14 mucormycosis 31.6 TNF IL6 IL10 CYP51A1 CRP CLEC7A
15 dermatophytosis 31.6 TNF IL1B IL17F IL17A CYP51A1 CLEC7A
16 parapsoriasis 31.5 CD8A CD4
17 tinea corporis 31.5 CLEC7A CLEC6A CD4 CARD9
18 tinea pedis 31.5 IL17A CYP51A1 CLEC7A CLEC6A CD4 CCR6
19 blastomycosis 31.5 TNF IL6 IL17A CYP51A1 CRP CLEC7A
20 follicular mucinosis 31.5 CD8A CD4
21 tinea capitis 31.5 CYP51A1 CLEC7A CLEC6A CD4 CARD9
22 phaeohyphomycosis 31.5 CLEC7A CLEC6A CARD9
23 tinea cruris 31.3 CYP51A1 CLEC6A CARD9
24 actinomycosis 31.3 TNF IL10 CRP CD4
25 tinea unguium 31.3 CYP51A1 CRP CARD9
26 acquired immunodeficiency syndrome 31.3 TNF IL6 IL1B IL10 CRP CD4
27 tinea imbricata 31.2 CLEC7A CLEC6A CARD9
28 penicilliosis 31.1 CLEC7A CD4 CARD9
29 granuloma annulare 31.1 TNF IL17A CD8A CD4
30 peripheral t-cell lymphoma 31.1 ICOSLG H2AC18 CD8A CD4 CCR6
31 lymphoma, non-hodgkin, familial 31.1 IL6 ICOSLG H2AC18 CD8A CD4 CCR6
32 dermatitis 31.0 TNF IL6 IL4 IL1B IL17A IL10
33 invasive aspergillosis 31.0 TNF TLR2 IL6 IL17A IL10 CYP51A1
34 vitiligo-associated multiple autoimmune disease susceptibility 1 31.0 TNF IL17A ICOSLG CD8A CD4 CCR6
35 meningitis 31.0 TNF TLR2 IL6 IL4 IL1B IL17A
36 neutropenia 31.0 TNF IL6 IL4 IL1B IL10 CRP
37 pneumocystosis 30.9 TNF IL6 IL17A IL10 CRP CLEC7A
38 spongiotic dermatitis 30.9 CD8A CD4 CCR6
39 lichen planus 30.9 TNF IL6 IL4 IL1B IL17A IL10
40 t-cell adult acute lymphocytic leukemia 30.9 CD8A CD4 CCR6
41 panniculitis 30.9 CRP CD8A CD4 CCR6
42 basal cell carcinoma 30.9 TNF IL6 ICOSLG H2AC18 CCR6
43 oral candidiasis 30.8 IL6 IL17RA IL17F IL17A CLEC7A CLEC6A
44 dermatomycosis 30.8 CYP51A1 CD4 CARD9
45 angioimmunoblastic t-cell lymphoma 30.8 ICOSLG CD8A CD4 CCR6
46 nocardiosis 30.8 TNF CRP CD4
47 leukemia, chronic lymphocytic 30.8 TNF IL6 IL4 IL10 ICOSLG H2AC18
48 telangiectasis 30.8 TNF H2AC18 CCR6
49 alopecia areata 30.8 TNF IL6 IL4 IL1B IL17A ICOSLG
50 histiocytosis 30.8 TNF IL4 IL17A CCR6

Graphical network of the top 20 diseases related to Fungal Infectious Disease:

Diseases related to Fungal Infectious Disease

Symptoms & Phenotypes for Fungal Infectious Disease

MGI Mouse Phenotypes related to Fungal Infectious Disease:

# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 AIRE CARD9 CCR6 CD4 CLEC7A CRP
2 immune system MP:0005387 10.3 AIRE CARD9 CCR6 CD4 CD8A CLEC6A
3 digestive/alimentary MP:0005381 10.11 AIRE CD4 CLEC7A CYP51A1 IL10 IL17A
4 no phenotypic analysis MP:0003012 10.09 AIRE CD4 CLEC6A CYP51A1 IL10 IL17A
5 hematopoietic system MP:0005397 10.09 AIRE CARD9 CCR6 CD4 CD8A CLEC6A
6 neoplasm MP:0002006 10 AIRE IL10 IL17RA IL1B IL6 TLR2
7 respiratory system MP:0005388 9.96 AIRE CLEC7A IL10 IL17A IL17F IL17RA
8 mortality/aging MP:0010768 9.8 AIRE CD4 CD8A CLEC6A CLEC7A CYP51A1
9 integument MP:0010771 9.32 CD4 CD8A IL10 IL17A IL17RA IL1B

Drugs & Therapeutics for Fungal Infectious Disease

Drugs for Fungal Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 305)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Voriconazole Approved Phase 4 137234-62-9 71616
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
Ibuprofen Approved Phase 4 15687-27-1 3672
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965
Sargramostim Approved, Investigational Phase 4 123774-72-1
Dimethyl sulfoxide Approved, Vet_approved Phase 4 67-68-5 679
Denileukin diftitox Approved, Investigational Phase 4 173146-27-5
Nystatin Approved, Vet_approved Phase 4 1400-61-9 11953884
Isavuconazole Approved, Investigational Phase 4 241479-67-4 21937662
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
Micafungin Approved, Investigational Phase 4 235114-32-6 477468
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 4112 126941
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
Molgramostim Investigational Phase 4 99283-10-0
19 Anti-Infective Agents Phase 4
20 Hormones Phase 4
21 Hormone Antagonists Phase 4
22 Antifungal Agents Phase 4
23 Cytochrome P-450 Enzyme Inhibitors Phase 4
24 Cytochrome P-450 CYP3A Inhibitors Phase 4
25 Cyclooxygenase Inhibitors Phase 4
26 Anti-Inflammatory Agents, Non-Steroidal Phase 4
27 Echinocandins Phase 4
28 Liposomal amphotericin B Phase 4
29 Amebicides Phase 4
30 Ionophores Phase 4
31 Liver Extracts Phase 4
Hydroxyitraconazole Phase 4 108222
33 Folic Acid Antagonists Phase 4
34 Folate Phase 4
35 Vitamin B9 Phase 4
36 Vitamin B Complex Phase 4
37 Pharmaceutical Solutions Phase 4
38 Interferon alpha-2 Phase 4
39 Interferon-alpha Phase 4
40 interferons Phase 4
Clorazepate Dipotassium Phase 4
Tolnaftate Approved, Investigational, Vet_approved Phase 3 2398-96-1 5510
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 2826718
Doripenem Approved, Investigational Phase 3 148016-81-3 73303
Rifabutin Approved, Investigational Phase 3 72559-06-9 46783538 6323490
Azithromycin Approved Phase 3 83905-01-5 447043
Betamethasone Approved, Vet_approved Phase 3 378-44-9 9782
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3 3680

Interventional clinical trials:

(show top 50) (show all 529)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety in Micafungin Sodium for Prophylaxis Against Invasive Fungal Disease During Neutropenia in Pediatric & Adolescent Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Unknown status NCT01135589 Phase 4 Micafungin
2 Safety of Fluconazole Treatment of Premature and Full-term Newborn Infants - A Study on Interactions by Nonsteroidal Anti Inflammatory Drugs (NSAIDs) With Fluconazole in Respect of Pharmacodynamic Endpoints With Urinary Excretion of Vasoactive Endobiotics Completed NCT02079298 Phase 4 Treatment with fluconazole.;2. Treatment with both fluconazole and Ibuprofen.;3. Treatment with ibuprofen.
3 Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure Completed NCT01968395 Phase 4 Caspofungin 70 mg
4 Anidulafungin Versus Fluconazole for the Prevention of Invasive Fungal Infections in High-risk Liver Transplant Recipients: a Randomized, Double-blind Trial Completed NCT00841971 Phase 4 Anidulafungin;Fluconazole
5 Clinical Study to Evaluate the Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors Completed NCT00336531 Phase 4 itraconazole
6 Effect of Granulocyte-macrophage Stimulating Factor on Prevention and Treatment of Invasive Fungal Diseases in the Recipients of Allogeneic Stem Cell Transplantation: A Prospective Multicenter Randomized Phase 4 Trial Completed NCT01232504 Phase 4 rhGM-CSF group;rhG-CSF+rhGM-CSF group;rhG-CSF group
7 Population Pharmacokinetic Analysis of Anidulafungin in Normal, Overweight and Obese Volunteers Completed NCT01307930 Phase 4 Anidulafungin
8 Fluconazole Pharmacokinetics, Including Bioavailability, in Obese Subjects After an Intravenous and Oral Administration (FOLIA) Completed NCT04122560 Phase 4 Fluconazole 200mg tab;Fluconazole 2 MG/ML
9 Comparison of Effectiveness of Topical Amphotericin B in 30% Dimethylsulphoxide and 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis: Randomized Double Blind Controlled Trial Pilot Study Completed NCT03814343 Phase 4 amphotericin B in 30% DMSO;30% DMSO
10 Single Dose Population Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients Completed NCT02968134 Phase 4 Posaconazole
11 An Open Label, Non-comparative, Multicenter Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infection Completed NCT00647907 Phase 4 Voriconazole
12 A Randomized Controlled Trial of the Effect of Cytochrome P450 2C19 Genotype-Specific Dosing Plus TDM vs. TDM Alone on Reaching Therapeutic Voriconazole Blood Levels Completed NCT03731169 Phase 4 Standard of Care
13 ANTIVORIFUNGOL:Strategy of Antifungal Use in Oncohematological Neutropenic Patients. Use of Voriconazole as Early Treatment. Completed NCT00386802 Phase 4 Antifungal drug. VORICONAZOL. (VFEND®)
14 A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole (SCH 56592) Among Patients With Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection Completed NCT00686543 Phase 4 Posaconazole
15 Prospective, Open-Label, Non-Comparative, Multicenter Study for the Secondary Prophylaxis of Invasive Fungal Infections (IFI) With Voriconazole in Patients With Allogeneic Stem Cell Transplants (SCT). Completed NCT00143312 Phase 4 voriconazole
16 Population Pharmacokinetic Analysis of Caspofungin in Overweight and Obese Volunteers Completed NCT01062165 Phase 4 Caspofungin
17 A Multicenter Open-Label Study to Evaluate the Safety and Efficacy of DAB389IL-2 in Cutaneous T-Cell Lymphoma (CTCL) Patients Following Protocol 93-04-10, Protocol 93-04-11, or Protocol 92-04-01 or Who Meet the Requirements for Protocol 93-04-11 Except Have Biopsy-Documented CTCL That Does Not Express CD25 Completed NCT00051012 Phase 4 ONTAK
18 A Multicenter Phase III Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Two Dose Levels of DAB389IL-2 (9 and 18 Mcg/kg/Day) in Cutaneous T-Cell Lymphoma (CTCL) Patients With Stage Ia-III Disease Who, Following Less Than or Equal to 3 Previous Therapies, Have Recurrent or Persistent Disease That Has Been Biopsy-Documented to Express CD25 Completed NCT00050999 Phase 4 ONTAK
19 Invasive Fungal Infection in Liver Transplant Recipients: A Randomized Double-Blind Trial Comparing AmBisome and Fluconazole in the High Risk Group and an Observational Cohort Study in the Low Risk Completed NCT00001107 Phase 4 Fluconazole;AmBisome
20 The Use of Antifungal Lock Therapy in Intestinal Failure and Other Patients Completed NCT00936910 Phase 4 amphotericin B liposomal (Ambisome)
21 Prediction of Itraconazole Oral Absorption From In Vitro Dissolution Completed NCT04035187 Phase 4 fast itraconazole tablet;medium itraconazole tablet;slow itraconazole tablet;oral itraconazole solution
22 Oral Nystatin Prophylaxis to Prevent Systemic Fungal Infection in Very Low Birth Weight Preterm Infants: a Randomized Controlled Trial Completed NCT03390374 Phase 4 Nystatin Oral
23 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Completed NCT02805946 Phase 4 posaconazole
24 UVADEX Sterile Solution in Conjunction With the UVAR XTS Photopheresis System as an Interventional Therapy for the Treatment Of CTCL (Mycosis Fungoides) in Patients With TMN Classification Stage 1A, 1B, 2A Completed NCT00221039 Phase 4 Methoxsalen+ECP
25 Assessment Of Voriconazole Penetration Into The Brain By Fluorine-Magnetic Resonance Spectroscopy Completed NCT00300677 Phase 4 voriconazole
26 An Open, Prospective, Uncontrolled, Multi-Center Study To Evaluate The Efficacy And Safety Of Voriconazole In Chinese Subjects With Proven Or Probable Serious Invasive Fungal Infections Completed NCT00288197 Phase 4 voriconazole
27 Multicenter, Randomized, Open-label Clinical Trial to Compare Anidulafungin Versus Amphotericin B Safety in High Risk Hepatic Transplant Recipients Completed NCT01303549 Phase 4 Anidulafungin;Liposomal amphotericin B
28 Efficacy of Itraconazole as Secondary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation or Chemotherapy With Prior Invasive Fungal Infection Completed NCT01198236 Phase 4 Itraconazole
29 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
30 A Prospective, Randomized Trial Comparing the Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing Completed NCT01416025 Phase 4 Prospective TDM Arm
31 A Randomized, Parallel, Single-Dose Study to Evaluate the Pharmacokinetics of Two Different Formulation of Voriconazole 200mg Tablets in Healthy Adult Subjects Completed NCT02912156 Phase 4 Vaway FC Tablets 200mg (Voriconazole);VFEND FC Tablets 200mg (Voriconazole)
32 Clinical Efficacy and Safety of Itraconazole Injection/Oral Solution Sequential Therapy for Treatment of Invasive Pulmonary Fungal Infections Completed NCT01823289 Phase 4 Itraconazole
33 Randomized and Multicenter Clinical Trial to Evaluate the Effectiveness and Efficiency of a Voriconazole Preemptive Genotyping Strategy in Patients With Risk of Aspergillosis Recruiting NCT04238884 Phase 4 Voriconazole preemptive genotyping strategy;Voriconazole clinical practice
34 Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Treatment With Oral Posaconazole Prophylaxis for Invasive Fungal Infection Recruiting NCT03717623 Phase 4 Posaconazole pharmacokinetics
35 Prospective, Observational and Cohort Clinical Research on Clinical Efficacy and Safety of Different Doses of Micafungin Sodium for Injection in Prevention and Treatment of Fungal Infection in Patients With Hematological Tumors Recruiting NCT04738955 Phase 4 Micafungin Sodium
37 To Evaluate the Efficacy and Safety of Micafungin in Preventing Invasive Mycosis After Liver Transplantation Not yet recruiting NCT04728971 Phase 4 Micafungin Sodium 50 MG Injection;Caspofungin Acetate
38 Itraconazole in the Management of Superficial Fungal Infections in India. A Pilot Study Terminated NCT03923010 Phase 4 Itraconazole
39 Prospective, Randomized Multicentic to Compare PUVA+IFN Alpha 2a vs PUVA Alone in Mycosis Fungoides Stages Ia, Ib or IIa. Terminated NCT00630903 Phase 4 PUVA (8MOP + UVA) + IFN;PUVA (8-MOP + UVA)
40 A Multi-center, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp Terminated NCT02646800 Phase 4 Micafungin
41 ProphyALL - Pilot Study on Safety of Four Weekly Administrations of 7 mg/kg of Liposomal Amphotericin B (AmBisome®) in Antifungal Primary Prophylaxis Treatment of Elderly Patients With Acute Lymphoblastic Leukemia Undergoing Induction Chemotherapy Within the GMALL-Elderly Protocol Terminated NCT00386997 Phase 4 liposomal amphotericin B (AmBisome®)
42 A Pharmacokinetic Analysis of Posaconazole in the Plasma and Alveolar Compartment of Lung Transplant Recipients Terminated NCT01667107 Phase 4 Posaconazole;Calogen®
43 Comparison of Methotrexate Versus Interferon-alfa 2b on Efficacy, Safety and Quality of Life in Patients With Primary Cutaneous T-cell Lymphomas Terminated NCT02323659 Phase 4 Methotrexate;Interferon Alfa-2b
44 Open Label, Limited Access Protocol of Posaconazole in Invasive Fungal Infections Study PO2095 Terminated NCT00177749 Phase 4 Posaconazole
45 Randomized, Open Label, Non-inferiority Study of Micafungin Versus Fluconazole for the Korean Prevention of Invasive Fungal Disease in Living Donor Liver Transplant Recipients Unknown status NCT01974375 Phase 3 micafungin;Fluconazole
46 Study Clinical, Multicenter, Phase III, to Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections Like Tinea Foot, Tinea and Tinea Crural Body" Unknown status NCT01105013 Phase 3 Clotrimazole
47 Combination Treatment of 5% Natamycin and 1% Voriconazole in Fungal Keratitis: a Prospective Randomized Double Masked Clinical Trial Unknown status NCT03230058 Phase 2, Phase 3 Group 1 Natamycin 5% Suspension + voriconazole 1% eye drops; Group 2 Natamycin 5% Suspension + Vehicle eye drops
48 Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis. Open Label Phase III Clinical Study Unknown status NCT01125644 Phase 3 SPK-843
49 Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides: A Randomized Controlled Trial Unknown status NCT03454945 Phase 3 Vibramycin
50 Open-Label, Non-Comparative Protocol for the Emergency Use of Voriconazole in Patients With Life Threatening, Invasive Mycoses Who Are Failing on Currently Available Antifungal Agents Completed NCT00015665 Phase 3 Voriconazole

Search NIH Clinical Center for Fungal Infectious Disease

Cochrane evidence based reviews: mycoses

Genetic Tests for Fungal Infectious Disease

Anatomical Context for Fungal Infectious Disease

Organs/tissues related to Fungal Infectious Disease:

MalaCards : Skin, Liver, T Cells, Bone Marrow, Myeloid, Lung, Eye

Publications for Fungal Infectious Disease

Articles related to Fungal Infectious Disease:

(show top 50) (show all 16232)
# Title Authors PMID Year
Ni/Ni(OH)2-rGO nanocomposites sensor for the detection of long forgotten mycotoxin, xanthomegnin. 62
36179558 2023
Treatment of the Candida subspecies Candida albicans and Candida parapsilosis with two far-UVC sources to minimise mycoses in clinical practice. 62
35986595 2023
Cytomorphology of Deep Mycoses in Dogs and Cats. 62
36270845 2023
Moving mycoses up the global agenda. 62
36400070 2022
The Impact of Paracoccidioides spp Infection on Central Nervous System Cell Junctional Complexes. 62
35922705 2022
Sporotrichosis in dogs: epidemiological and clinical-therapeutic profile and the emergence of itraconazole-resistant isolates. 62
36455616 2022
Update of the Epidemiology of the Sporotrichosis Epidemic in the state of Rio Grande do Sul, Brazil. 62
35833311 2022
Cutaneous chromoblastomycosis mimicking melanoma in a renal transplant recipient. 62
36393996 2022
Current situation of endemic mycosis in the Americas and the Caribbean: Proceedings of the first international meeting on endemic mycoses of the Americas (IMEMA). 62
35971917 2022
Invasive mucormycosis in a tertiary care hospital in the western region of Saudi Arabia: 11-year retrospective chart review from 2009 to 2019. 62
36403403 2022
Pharmacokinetics of fluconazole after oral administration to healthy beagle dogs. 62
36000582 2022
Atorvastatin-loaded emulsomes foam as a topical antifungal formulation. 62
36465276 2022
[Chronic pulmonary mycosis due to Paracoccidioides brasiliensis]. 62
36260755 2022
Scedosporium apiospermum mediastinitis in an orthotopic heart transplant recipient. 62
36277499 2022
Changes of the gene expression in silkworm larvae and Cordyceps militaris at late stages of the pathogenesis. 62
36116100 2022
Pathogenicity & virulence of Histoplasma capsulatum - A multifaceted organism adapted to intracellular environments. 62
36266777 2022
Interleukin (IL)-33 immunobiology in asthma and airway inflammatory diseases. 62
34928757 2022
Double CD4/CD8-Positive, Nonpoikilodermic Mycosis Fungoides Expressing CD56 in a Young Man. 62
35925554 2022
Syringotropic Mycosis Fungoides: A Variant of Folliculotropic or a Distinct Subtype of Adnexotropic Mycosis Fungoides? 62
36468959 2022
Mycosis fungoides in pediatric population: comprehensive review on epidemiology, clinical presentation, and management. 62
35193164 2022
Maintenance and Concomitant Therapy Use with Chlormethine Gel Among Patients with Stage IA/IB Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Real-World Evidence Study. 62
36284059 2022
A case of erythrodermic mycosis fungoides responding to upadacitinib. 62
36411841 2022
A cross-sectional analysis of Google images of mycosis fungoides: is dark skin adequately represented? 62
36468820 2022
Response to "Mycosis fungoides in pediatric population: comprehensive review on epidemiology, clinical presentation, and management". 62
35965350 2022
Correction to: Efficacy of narrowband UVB phototherapy in early‑stage mycosis fungoides in Iranian patients. 62
35881209 2022
Expression pattern and diagnostic utility of BCL11B in mature T- and NK-cell neoplasms. 62
35864006 2022
Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study. 62
35895386 2022
Itch in patients with cutaneous T-cell lymphoma as a quality of life indicator. 62
36147217 2022
Evaluation of clonality from multiple anatomic sites in canine epitheliotropic T cell lymphoma. 62
35876313 2022
Cutaneous Lymphocyte Antigen Is a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma. 62
35850209 2022
Influenza vaccination is associated with a reduced risk of invasive aspergillosis in high-risk individuals in Taiwan: a population-based cohort study. 62
36469743 2022
Distinguishing Invasive from Chronic Pulmonary Infections: Host Pentraxin 3 and Fungal Siderophores in Bronchoalveolar Lavage Fluids. 62
36422015 2022
Susceptibility and characteristics of infections in patients with glucocorticoid excess or insufficiency: the ICARO tool. 62
36102827 2022
Impact of revised EORTC/MSGERC 2020 criteria on diagnosis and prognosis of invasive pulmonary aspergillosis in patients with hematological malignancies undergoing bronchoscopy. 62
35738036 2022
Treatments of refractory eosinophilic lung diseases with biologics. 62
36333218 2022
Exploring the most visible websites on cutaneous T-cell lymphoma-revealing limited quality of patient health information on the internet. 62
35842932 2022
A novel mouse model of cutaneous T-cell lymphoma revealed the combined effect of mogamulizumab with psoralen and ultraviolet a therapy. 62
35801380 2022
Development of indirect ELISA and its evaluation in comparison with KOH hydrolysis and fungal culture for the immuno diagnosis of Trichophyton rubrum and Trichophyton mentagrophytes infection in humans. 62
35907501 2022
Performance of the JF5-Based Galactomannoprotein EIA Compared to the Lateral Flow Device and the Galactomannan EIA in Serum and Bronchoalveolar Lavage Fluid. 62
36214562 2022
Anti-Aspergillus fumigatus IgG in patients with bronchiectasis and its relationship with clinical outcome. 62
36434134 2022
Using infrared spectroscopy of serum and chemometrics for diagnosis of paracoccidioidomycosis. 62
36113324 2022
Nascent Nanoformulations as an Insight Into the Limitations of the Conventional Systemic Antifungal Therapies. 62
36443967 2022
Preliminary Investigation about Aspergillus spp. Spread in Umbrian Avian Farms. 62
36422034 2022
Osteoarticular Mycoses. 62
36448782 2022
The first report of tinea nigra from Iran. 62
36276912 2022
Cutaneous T cell lymphoma treated with mogamulizumab monotherapy and mogamulizumab plus etoposide combined therapy: A real-world case series. 62
36161437 2022
Risk of Non-cutaneous Cancers in Individuals with Basal Cell Carcinoma: A Population-based Cohort Study. 62
36448850 2022
Mogamulizumab and bexarotene are a promising association for the treatment of advanced cutaneous T-cell lymphomas: a case series. 62
36394762 2022
Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma. 62
36429020 2022
Single-cell analyses reveal novel molecular signatures and pathogenesis in cutaneous T cell lymphoma. 62
36400759 2022

Variations for Fungal Infectious Disease

Expression for Fungal Infectious Disease

Search GEO for disease gene expression data for Fungal Infectious Disease.

Pathways for Fungal Infectious Disease

Pathways related to Fungal Infectious Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
Show member pathways
13.89 TNF TLR2 IL6 IL4 IL1B IL17RA
Show member pathways
13.83 TNF IL6 IL4 IL1B IL17RA IL17A
Show member pathways
13.66 TNF IL6 IL4 IL1B IL17RA IL17F
Show member pathways
13.44 CCR6 CD4 IL10 IL17A IL17RA IL1B
Show member pathways
13.36 TNF IL6 IL4 IL1B IL17RA IL17F
Show member pathways
13.33 TNF IL6 IL4 IL1B IL17RA IL17A
Show member pathways
Show member pathways
12.67 TNF IL6 IL4 IL1B IL17A IL10
9 12.65 TNF TLR2 IL4 IL1B IL17A IL10
Show member pathways
12.64 TNF IL6 IL1B IL17F IL17A IL10
Show member pathways
Show member pathways
12.47 IL1B IL4 IL6 TLR2 TNF
Show member pathways
Show member pathways
12.35 TNF TLR2 IL6 IL17RA IL17F IL17A
Show member pathways
12.22 TNF IL4 IL17A IL10 CD8A CD4
16 12.19 TNF IL6 IL1B IL10
17 12.17 TNF IL6 IL4 IL1B IL10
18 12.09 CD4 CD8A IL10 IL4 IL6 TNF
19 12.04 TNF IL6 IL4 IL1B
Show member pathways
12.02 IL4 IL1B CD8A CD4
21 12.01 TNF IL6 IL4 IL1B IL17F IL17A
22 11.96 TNF IL4 IL1B IL17A IL10
Show member pathways
11.93 IL6 IL17RA IL17F IL17A
Show member pathways
11.83 IL6 CRP CD8A CD4
25 11.82 TNF IL6 IL4 IL10 ICOSLG CRP
26 11.79 IL6 IL4 IL1B IL17F IL17A CD4
27 11.78 TNF IL6 IL1B IL17RA IL10 CD8A
28 11.77 TNF IL6 IL1B
29 11.76 IL6 IL10 CD4
Show member pathways
11.76 TNF TLR2 IL6 IL1B IL17F IL17A
31 11.74 TNF IL6 IL4 IL1B
32 11.73 IL6 IL4 IL10
33 11.73 IL10 IL1B IL6 TNF
Show member pathways
11.7 IL10 IL17F IL4 IL6 TLR2 TNF
Show member pathways
11.68 TNF IL6 IL1B
36 11.67 TNF IL6 IL10
37 11.59 TNF IL4 IL10 CD4
38 11.59 IL10 IL1B IL6 TNF
39 11.56 TNF TLR2 IL1B
40 11.53 CD4 IL10 IL4
41 11.52 TNF IL6 IL1B
Show member pathways
11.52 TLR2 IL6 IL4 IL1B IL17RA IL17F
43 11.45 TNF IL6 IL1B IL10
44 11.43 TNF IL6 IL4 IL1B IL17A
45 11.36 TNF IL6 IL1B IL17F IL17A
46 11.33 TNF IL6 IL1B
47 11.26 CD4 IL10 IL1B IL4 IL6 TNF
48 11.17 TNF IL6 IL4 IL17F IL17A IL10
49 11.16 IL6 IL1B IL10
50 11.13 TNF IL4 IL1B IL17A IL10 CD8A

GO Terms for Fungal Infectious Disease

Cellular components related to Fungal Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.47 TNF IL17A ICOSLG CLEC6A CD8A CD4

Biological processes related to Fungal Infectious Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.64 AIRE IL10 IL17A IL17F IL1B IL4
2 positive regulation of gene expression GO:0010628 10.5 CLEC7A CRP IL1B IL4 IL6 TLR2
3 innate immune response GO:0045087 10.46 TLR2 IL17RA IL17F IL17A CRP CLEC7A
4 inflammatory response GO:0006954 10.39 CLEC7A CRP IL17A IL17F IL17RA IL1B
5 adaptive immune response GO:0002250 10.37 CARD9 CD4 CD8A CLEC6A ICOSLG IL17A
6 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.34 TNF IL1B CLEC7A CLEC6A CD4 CARD9
7 positive regulation of DNA-binding transcription factor activity GO:0051091 10.3 TNF IL6 IL1B IL10 CLEC7A
8 positive regulation of inflammatory response GO:0050729 10.29 TNF TLR2 IL1B IL17RA
9 defense response to Gram-negative bacterium GO:0050829 10.27 IL6 IL17F IL17A CD4
10 positive regulation of tumor necrosis factor production GO:0032760 10.27 CARD9 CLEC7A IL17A IL6 TLR2
11 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.25 TNF TLR2 IL6 IL1B CLEC7A CARD9
12 positive regulation of interleukin-1 beta production GO:0032731 10.24 CLEC7A IL17A IL6 TNF
13 humoral immune response GO:0006959 10.23 TNF IL6 CCR6 AIRE
14 positive regulation of interleukin-12 production GO:0032735 10.2 TLR2 IL17A CLEC7A
15 positive regulation of nitric oxide biosynthetic process GO:0045429 10.19 TNF IL1B CLEC7A
16 lipopolysaccharide-mediated signaling pathway GO:0031663 10.19 IL1B TLR2 TNF
17 positive regulation of interleukin-10 production GO:0032733 10.19 TLR2 IL6 IL4 CLEC7A
18 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.18 TNF IL6 IL10
19 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 10.18 TNF IL1B CLEC7A
20 positive regulation of interleukin-2 production GO:0032743 10.18 CD4 CLEC7A IL1B
21 defense response to fungus GO:0050832 10.18 CLEC6A IL17A IL17RA
22 positive regulation of interleukin-8 production GO:0032757 10.18 CLEC7A IL1B IL6 TLR2 TNF
23 immune response GO:0006955 10.18 TNF TLR2 IL6 IL4 IL1B IL17A
24 liver regeneration GO:0097421 10.16 TNF IL6 IL10
25 T cell activation GO:0042110 10.16 IL4 ICOSLG CLEC7A CD8A CD4
26 defense response to Gram-positive bacterium GO:0050830 10.16 CARD9 CRP IL17A IL17F IL1B IL6
27 microglial cell activation GO:0001774 10.15 TNF TLR2 IL4
28 negative regulation of neurogenesis GO:0050768 10.15 IL1B IL6 TNF
29 positive regulation of cytokine production GO:0001819 10.14 TNF IL1B IL17F IL10 CLEC6A CARD9
30 antifungal innate immune response GO:0061760 10.12 CLEC7A CLEC6A CARD9
31 positive regulation of glial cell proliferation GO:0060252 10.12 TNF IL6 IL1B
32 positive regulation of heterotypic cell-cell adhesion GO:0034116 10.1 TNF IL1B IL10
33 positive regulation of T-helper 17 type immune response GO:2000318 10.09 CARD9 CLEC6A CLEC7A
34 positive regulation of neuroinflammatory response GO:0150078 10.08 IL1B IL6 TNF
35 negative regulation of lipid storage GO:0010888 10.07 TNF IL6 CRP
36 immune system process GO:0002376 10.07 CARD9 CD4 CD8A CLEC6A CLEC7A ICOSLG
37 positive regulation of chemokine production GO:0032722 10.06 TNF TLR2 IL6 IL1B CARD9 AIRE
38 interleukin-17-mediated signaling pathway GO:0097400 10.05 IL17RA IL17F IL17A
39 positive regulation of mononuclear cell migration GO:0071677 10.02 TNF IL4
40 negative regulation of cytokine production involved in immune response GO:0002719 10.02 TNF IL10
41 cell activation GO:0001775 10.02 TNF TLR2 CLEC7A
42 positive regulation of interleukin-23 production GO:0032747 10.02 IL17RA IL17A CLEC7A
43 positive regulation of fever generation GO:0031622 10.01 TNF IL1B
44 regulation of interleukin-8 production GO:0032677 10.01 IL17F CRP
45 vascular endothelial growth factor production GO:0010573 10.01 TNF IL6 IL1B
46 fibroblast activation GO:0072537 10 IL17RA IL17A
47 regulation of isotype switching GO:0045191 9.99 IL4 IL10
48 sequestering of triglyceride GO:0030730 9.99 TNF IL1B
49 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.98 TNF IL1B
50 regulation of interleukin-2 production GO:0032663 9.97 IL17F CARD9

Molecular functions related to Fungal Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.47 TNF IL6 IL4 IL1B IL17F IL17A
2 pattern recognition receptor activity GO:0038187 9.43 TLR2 CLEC7A CLEC6A

Sources for Fungal Infectious Disease

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....